Switching From Tirzepatide to Retatrutide
No published clinical protocol exists for switching from tirzepatide to retatrutide. Retatrutide is not FDA approved. Any transition between these drugs should be managed by a licensed physician. The pharmacological considerations for switching are not established in clinical literature.
Why People Ask About Switching
People currently on tirzepatide (Zepbound or Mounjaro) ask about switching to retatrutide because retatrutide's Phase 3 data shows greater weight loss in cross-trial comparisons. Tirzepatide activates GLP-1 and GIP receptors; retatrutide adds glucagon receptor agonism, which may contribute to greater energy expenditure and fat loss.
Mechanism Overlap and Differences
Tirzepatide and retatrutide share GLP-1 and GIP receptor agonism. Retatrutide adds glucagon receptor agonism. The glucagon receptor activation in retatrutide increases energy expenditure and reduces hepatic fat — effects not present with tirzepatide. This additional mechanism is the primary theoretical basis for retatrutide's greater weight loss.
Current Availability Status
Retatrutide is not FDA approved and is not commercially available as of September 2026. Eli Lilly has announced plans for a Q1 2027 regulatory submission. FDA approval and commercial availability are not guaranteed. Switching from tirzepatide to retatrutide is not currently possible outside a clinical trial.
Questions about retatrutide? A licensed physician can review your case.
Start Physician Review